Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) EBITDA Margin (2016 - 2022)

Historic EBITDA Margin for Aptevo Therapeutics (APVO) over the last 8 years, with Q1 2022 value amounting to 180.19%.

  • Aptevo Therapeutics' EBITDA Margin rose 1043200.0% to 180.19% in Q1 2022 from the same period last year, while for Dec 2022 it was 919.75%, marking a year-over-year decrease of 7456500.0%. This contributed to the annual value of 919.75% for FY2022, which is 7456500.0% down from last year.
  • Latest data reveals that Aptevo Therapeutics reported EBITDA Margin of 180.19% as of Q1 2022, which was up 1043200.0% from 110.23% recorded in Q4 2021.
  • In the past 5 years, Aptevo Therapeutics' EBITDA Margin registered a high of 105.97% during Q4 2019, and its lowest value of 1439.11% during Q2 2020.
  • Over the past 5 years, Aptevo Therapeutics' median EBITDA Margin value was 182.3% (recorded in 2018), while the average stood at 290.61%.
  • As far as peak fluctuations go, Aptevo Therapeutics' EBITDA Margin crashed by -12638900bps in 2020, and later soared by 12551200bps in 2021.
  • Quarter analysis of 5 years shows Aptevo Therapeutics' EBITDA Margin stood at 208.22% in 2018, then skyrocketed by 49bps to 105.97% in 2019, then plummeted by -171bps to 287.36% in 2020, then surged by 62bps to 110.23% in 2021, then crashed by -63bps to 180.19% in 2022.
  • Its last three reported values are 180.19% in Q1 2022, 110.23% for Q4 2021, and 153.42% during Q3 2021.